The drugmaker lost 18 cents a share in Q4, a penny worse than last year and 4 cents below forecasts. Halozyme Therapeutics' (NASDAQ:HALO - News) revenue fell 32% to $2.4 mil, far below estimates of $6.2 mil, after it ended a partnership with Baxter Int'l (NYSE:BAX - News). Halozyme said Roche (OTCPK:RHHBY) filed for marketing approval of a new version of its breast cancer drug Herceptin. Halozyme dipped 1% to 11.39.
The Federal Reserve will keep its version of the monetary printing press running a while longer, though Chairman …